The pace of hepatitis C virus (HCV) drug development in recent years has accelerated
dramatically. For patients to benefit from these impressive advances, practitioners need …

Acute-on-chronic liver failure combines an acute deterioration in liver function in an
individual with pre-existing chronic liver disease and hepatic and extrahepatic organ …

Nonalcoholic fatty liver disease (NAFLD) is a major cause of chronic liver disease. There is
uncertainty around the economic burden of NAFLD. We constructed a steady‐state …

Background & Aims In phase III trials, the safety profile of triple therapy (pegylated
interferon/ribavirin with boceprevir or telaprevir) seems to be similar in HCV treatment …

Background & Aims We investigated the effectiveness of the protease inhibitors
peginterferon and ribavirin in treatment-experienced patients with hepatitis C virus (HCV) …

Liver resection (LR) for hepatocellular carcinoma (HCC) as the first‐line treatment in
transplantable patients followed by “salvage transplantation”(ST) in case of recurrence is an …

In patients with chronic hepatitis C (CHC), cirrhosis is associated with age, gender, diabetes,
alcohol abuse, and coinfection with human immunodeficiency virus (HIV) or hepatitis B virus …

Abstract Lipocalin‐2 (LCN2), also known as neutrophil gelatinase‐associated lipocalin
(NGAL), a key antibacterial protein, is highly elevated in patients with end‐stage liver …

The natural history of cirrhosis can be divided into an initial stage, known as compensated
cirrhosis, and an advanced stage which encompasses both decompensated cirrhosis and …

Background An all‐oral, pegylated interferon (peg IFN)‐free and ribavirin (RBV)‐free single‐
tablet of ledipasvir (LDV) and sofosbuvir (SOF) is now approved for the treatment of patients …